Steroidal Compositions

Abstract

Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein.

What is claimed is: 
     
         1 . A method of treating a hypogonadal male comprising orally administering to the male twice-daily a composition comprising a capsule and a semi-solid formulation encased within the capsule, the formulation comprising:
 a) 20-25 percent by weight of testosterone undecanoate (TU),   b) 10-21 percent by weight of hydrophilic surfactant, and   c) 48-70 percent by weight of lipophilic carrier selected from lipophilic surfactant, triglycerides, or Vitamin E compounds,   wherein the formulation in the capsule administered twice daily comprises about 120 mg to about 400 mg of TU, and wherein the composition, when orally administered to a plurality of hypogonadal males provides, a mean plasma concentration of testosterone at steady state of between 300 ng/dL and 1000 ng/dL in at least 75% of the males, a plasma C max  concentration of testosterone less than 1800 ng/dL in at least 95% of males, less than 1500 ng/dL in at least 85% of males, and less than 2500 ng/dL in all males.   
     
     
         2 . The method of  claim 1 , wherein administration of the composition provides a serum T max  at 3 to 9 hours. 
     
     
         3 . The method of  claim 1 , wherein the formulation further comprises a 5-alpha reductase inhibitor. 
     
     
         4 . The method of  claim 1 , wherein the formulation further comprises a digestible oil. 
     
     
         5 . The method of  claim 4 , wherein the hydrophilic surfactant is polyoxyethylene (40) hydrogenated castor oil and the lipophilic surfactant is oleic acid. 
     
     
         6 . The method of  claim 1 , wherein the composition releases about 40 wt. % TU within the first 30 minutes and about 60 wt. % TU after 4 hours in an aqueous medium. 
     
     
         7 . The method of  claim 1 , wherein the formulation in the capsule administered twice daily comprises about 120 mg to about 240 mg of TU.